200,000+ products from a single source!
sales@angenechem.com
149908-53-2 | 2,4-Imidazolidinedione, 1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-
CAS No: 149908-53-2 Catalog No: AG001M3N MDL No:
Product Description
Catalog Number:
AG001M3N
Chemical Name:
2,4-Imidazolidinedione, 1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-
CAS Number:
149908-53-2
Molecular Formula:
C23H28ClN5O3
Molecular Weight:
457.9531
IUPAC Name:
1-[(E)-[5-(4-chlorophenyl)furan-2-yl]methylideneamino]-3-[4-(4-methylpiperazin-1-yl)butyl]imidazolidine-2,4-dione
InChI:
InChI=1S/C23H28ClN5O3/c1-26-12-14-27(15-13-26)10-2-3-11-28-22(30)17-29(23(28)31)25-16-20-8-9-21(32-20)18-4-6-19(24)7-5-18/h4-9,16H,2-3,10-15,17H2,1H3/b25-16+
InChI Key:
MREBEPTUUMTTIA-PCLIKHOPSA-N
SMILES:
CN1CCN(CC1)CCCCN1C(=O)CN(C1=O)N=Cc1ccc(o1)c1ccc(cc1)Cl
Properties
Complexity:
677
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
1
Exact Mass:
457.188g/mol
Formal Charge:
0
Heavy Atom Count:
32
Hydrogen Bond Acceptor Count:
6
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
457.959g/mol
Monoisotopic Mass:
457.188g/mol
Rotatable Bond Count:
8
Topological Polar Surface Area:
72.6A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.2
Literature
| Title | Journal |
|---|---|
| A mechanism underlying compound-induced voltage shift in the current activation of hERG by antiarrhythmic agents. | Biochemical and biophysical research communications 20111111 |
| I(Kr) vs. I(Ks) blockade and arrhythmogenicity in normoxic rabbit Purkinje fibers: does it really make a difference? | Fundamental & clinical pharmacology 20110601 |
| [The research practice of anti-arrhythmic agents targeting on potassium ion channel]. | Yao xue xue bao = Acta pharmaceutica Sinica 20110101 |
| Inhibitory effect of azimilide on Na+/Ca2+ exchange current in guinea-pig cardiac myocytes. | Journal of pharmacological sciences 20100101 |
| Molecular hybridization, synthesis, and biological evaluation of novel chroman I(Kr) and I(Ks) dual blockers. | Bioorganic & medicinal chemistry letters 20090301 |
| Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial. | Journal of the American College of Cardiology 20080923 |
| Azimilide: another effort to prevent implantable cardioverter-defibrillator shocks and their sequelae why it is important and how it works. | Journal of the American College of Cardiology 20080923 |
| New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? | The American journal of cardiology 20080922 |
| Role of drug therapy for sustained ventricular tachyarrhythmias. | Cardiology clinics 20080801 |
| Update on atrial fibrillation: part II. | Clinical cardiology 20080301 |
| Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias. | Journal of cardiovascular electrophysiology 20080201 |
| The impact of acute myocardial ischemia on the ventricular defibrillation threshold during chronic oral azimilide therapy. | Journal of cardiovascular pharmacology 20071201 |
| Effects of azimilide on the muscarinic acetylcholine receptor-operated K+ current and experimental atrial fibrillation in guinea-pig hearts. | Journal of pharmacological sciences 20071101 |
| Adjunctive therapy for recurrent ventricular tachycardia in patients with implantable cardioverter defibrillators. | Current cardiology reports 20070901 |
| QT Interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator. | Pacing and clinical electrophysiology : PACE 20070801 |
| Antiarrhythmic drugs: present and future. | The Journal of the Association of Physicians of India 20070401 |
| L-type calcium current reactivation contributes to arrhythmogenesis associated with action potential triangulation. | Journal of cardiovascular electrophysiology 20070201 |
| Action potential and QT prolongation not sufficient to cause Torsade de Pointes: role of action potential triangulation. | Journal of cardiovascular electrophysiology 20070201 |
| The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents. | Cardiology 20070101 |
| Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial. | European heart journal 20061201 |
| Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial. | European heart journal 20060901 |
| Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database. | Journal of the American College of Cardiology 20060801 |
| Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. | The American journal of cardiology 20060715 |
| Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro. | Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20060701 |
| Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. | American heart journal 20060501 |
| Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. | Journal of cardiovascular pharmacology 20060101 |
| The metabolic profile of azimilide in man: in vivo and in vitro evaluations. | Journal of pharmaceutical sciences 20050901 |
| Electrophysiological effects of azimilide in an in vitro model of simulated-ischemia and reperfusion in guinea-pig ventricular myocardium. | European journal of pharmacology 20050822 |
| Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. | Journal of cardiovascular electrophysiology 20050801 |
| Application of Raman spectroscopy for on-line monitoring of low dose blend uniformity. | International journal of pharmaceutics 20050714 |
| Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin. | Journal of clinical pharmacology 20050701 |
| Azimilide dihydrochloride. | Expert review of cardiovascular therapy 20050501 |
| The influence of extracellular acidosis on the effect of IKr blockers. | Journal of cardiovascular pharmacology and therapeutics 20050301 |
| Design of the SHock Inhibition Evaluation with Azimilide (SHIELD) study: a novel method to assess antiarrhythmic drug effect in patients with an implantable cardioverter-defibrillator. | The American journal of cardiology 20050115 |
| Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. | Circulation 20041214 |
| The shocking story of azimilide. | Circulation 20041214 |
| Influence of ketoconazole on azimilide pharmacokinetics in healthy subjects. | British journal of clinical pharmacology 20041201 |
| Advantages and pitfalls of combining device-based and pharmacologic therapies for the treatment of ventricular arrhythmias: observations from a tertiary referral center. | Pacing and clinical electrophysiology : PACE 20041201 |
| A benefit-risk assessment of class III antiarrhythmic agents. | Expert opinion on drug safety 20041101 |
| State-dependent blocking actions of azimilide dihydrochlo-ride (NE-10064) on human cardiac Na(+) channels. | Circulation journal : official journal of the Japanese Circulation Society 20040701 |
| Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs. | Medical science monitor : international medical journal of experimental and clinical research 20040701 |
| Effect of mild and moderate hepatic impairment on azimilide pharmacokinetics following single dose oral administration. | Journal of pharmaceutical sciences 20040501 |
| Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels. | Basic & clinical pharmacology & toxicology 20040501 |
| The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. | Journal of the American College of Cardiology 20040407 |
| Influence of azimilide on CYP2C19-mediated metabolism. | Journal of clinical pharmacology 20040401 |
| Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. | Circulation 20040302 |
| Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. | Journal of the American College of Cardiology 20040107 |
| Oral class III antiarrhythmics: what is new? | Current opinion in cardiology 20040101 |
| Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation. | Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 20040101 |
| Recent developments in cardiovascular drug therapy: treatment of atrial arrhythmias with new class III drugs and beyond. | Current medicinal chemistry. Cardiovascular and hematological agents 20040101 |
| [Progress in the clinical use of anti-arrhythmic drugs (I)]. | Zhonghua er ke za zhi = Chinese journal of pediatrics 20031001 |
| Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. | American heart journal 20030901 |
| Pure class III agents for prevention of sudden cardiac death. | Journal of cardiovascular electrophysiology 20030901 |
| Azimilide for atrial fibrillation: clinical trial results and implications. | Cardiac electrophysiology review 20030901 |
| Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. | Bioorganic & medicinal chemistry letters 20030818 |
| Multiple cellular electrophysiological effects of azimilide in canine cardiac preparations. | European journal of pharmacology 20030606 |
| Preserved effects of potassium channel blockers in the pacing-induced remodeled canine atrium: a comparison between E4031 and azimilide. | Journal of cardiovascular pharmacology 20030501 |
| Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. | The American journal of cardiology 20030320 |
| Asymptomatic or 'silent' atrial fibrillation: frequency in untreated patients and patients receiving azimilide. | Circulation 20030304 |
| Block of erg current by linoleoylamide, a sleep-inducing agent, in pituitary GH3 cells. | European journal of pharmacology 20030101 |
| Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide. | Naunyn-Schmiedeberg's archives of pharmacology 20021101 |
| Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration. | British journal of clinical pharmacology 20021101 |
| [Drug therapy of ventricular arrhythmias - a contemporary perspective]. | Deutsche medizinische Wochenschrift (1946) 20021025 |
| The effect of isoproterenol on the class III effect of azimilide in humans. | Journal of cardiovascular pharmacology and therapeutics 20021001 |
| Azimilide inhibits multiple cardiac potassium currents in human atrial myocytes. | Journal of cardiovascular pharmacology and therapeutics 20021001 |
| [Current strategies of pharmacological and non-pharmacological treatment in atrial fibrillation and atrial flutter]. | Nihon rinsho. Japanese journal of clinical medicine 20020701 |
| Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response. | American heart journal 20020401 |
| Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation. | Journal of clinical pharmacology 20020401 |
| New antiarrhythmic drugs for the treatment of atrial fibrillation. | Pacing and clinical electrophysiology : PACE 20020201 |
| Cardiovascular news. | Circulation 20011127 |
| Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. | The American journal of cardiology 20011101 |
| Interaction of azimilide with neurohumoral and channel receptors. | Biochemical pharmacology 20011001 |
| A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide. | Clinical pharmacology and therapeutics 20011001 |
| Is it rational, reasonable or excessive, and consistently applied? One view of the increasing FDA emphasis on safety first for the release and use of antiarrhythmic drugs for supraventricular arrhythmias. | Journal of cardiovascular pharmacology and therapeutics 20011001 |
| Efficacy of azimilide and dofetilide in the dog right atrial enlargement model of atrial flutter. | Journal of cardiovascular electrophysiology 20010901 |
| Effects of azimilide, a new class III antiarrhythmic drug, on reentrant circuits causing ventricular tachycardia and fibrillation in a canine model of myocardial infarction. | Journal of cardiovascular electrophysiology 20010901 |
| Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall. | Circulation 20010612 |
| Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias. | European journal of pharmacology 20010119 |
| Newer antiarrhythmic drugs. | Indian heart journal 20010101 |
| New antiarrhythmic agents for atrial fibrillation. | Current opinion in investigational drugs (London, England : 2000) 20010101 |
| Azimilide dihydrochloride: a new class III anti-arrhythmic agent. | Expert opinion on investigational drugs 20001101 |
| Effects of azimilide, a KV(r) and KV(s) blocker, on canine ventricular arrhythmia models. | European journal of pharmacology 19990702 |
| Azimilide dihydrochloride: a unique class III antiarrhythmic agent. | Heart disease (Hagerstown, Md.) 19990101 |
| The azimilide post-infarct survival evaluation (ALIVE) trial. | The American journal of cardiology 19980319 |
| Inhibition of isoproterenol-induced tachycardia by azimilide in the isolated perfused guinea pig heart. | Cardiovascular drugs and therapy 19980301 |
| The role of the IsK protein in the specific pharmacological properties of the IKs channel complex. | British journal of pharmacology 19970901 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.